Merck Strengthens Commitment to Chinese Growth Market
Merck KGaA, has reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.
Merck’s Executive Board this week met in Shanghai, a month before the groundbreaking of its new pharmaceutical plant in Nantong, which from 2017 will be the group’s second-largest pharmaceutical manufacturing facility globally.
Merck currently employs more than 2,000 people at over 40 sites in China, with the most important products including Erbitux to treat cancer, Gonal-f to treat infertility, as well as life science tools and liquid crystals (LC) for flat panel displays. In total, Merck has committed more than €100 million to investments in China over the past 3 years.
“China is of strategic importance to Merck,” said Karl-Ludwig Kley, Chairman of the Executive Board. “Together with government officials, customers, partners and our highly motivated local colleagues, we will explore ways to further address critical healthcare needs of the Chinese population — both with our high-quality drugs and our life science tools for biopharmaceutical R&D. We’re also meeting with customers in the display industry to continue our constant dialogue about innovative solutions to meet the needs of the ever-changing high-tech market.”
Merck has a strong presence in the fast-growing emerging markets: aales in the region, which includes China, grew by 9% to around €3.8 billion last year, contributing 36% to group total sales of €10.7 billion in 2013.
Next month, groundbreaking is planned for Merck’s new €80 million (650 million Yuan) pharmaceutical manufacturing plant in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area). Completion of the facility, which will focus on bulk production and packaging of Glucophage, Concor and Euthyrox, is scheduled for 2016, with commercial production starting in 2017. Merck’s brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders are referenced in China’s Essential Drug List (EDL), making Merck the first and only multinational company in China to dedicate a large-scale green-field investment towards the production of drugs on the list comprising medicines that satisfy public healthcare needs and must be made available at all times.
In addition to investments in drug production, Merck has also expanded its services for biopharmaceutical R&D customers. Recent investments by the Merck Millipore life science tools business include the Biopharmaceutical Technical and Training Centre in Zhangjiang Hi-Tech Park, Shanghai. This center provides support, training and validation services to biopharmaceuticals customers with operations in China. The facility enables customers to investigate, explore and optimise their upstream and downstream processes, as well as environmental monitoring processes. In Beijing, where Merck Serono’s Chinese headquarters are located, Merck also runs a research center focused on biomarker research, including pharmacogenomics and bioanalytics, which is part of Merck Serono’s stratified medicine approach.
In addition to these investments, Merck counts on an extensive network of collaborations with leading academic and medical institutions in China, as well as local companies. The latest collaboration agreement with a Chinese company, announced in November 2013, is a second co-development and commercialisation agreement with BeiGene, which will further strengthen the companies’ collaboration in oncology.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance